India's first anti-microbial roll-on 'CoviRaksha' launched for treatment of COVID-19: All you need to know

While many companies, health experts are working around to make a cure for prevention of COVID-19 virus, Nutan Labs, a nanotechnology-based startup on Tuesday launched an Ayurvedic proprietary medicine that helps in preventing the virus and also in the treatment of the disease.

The first of its kind start-up in India, IISc Bengaluru tested the proprietary medicine on 10,000 people who were not infected by the virus. The research conducted showed that it helps in increasing oxygen saturation by helping decongest respiratory tract, and residual symptoms of covid, reducing coughing and sore throat.

As per a Times Now report, Nutan, Founder of Nutan Labs, said, “Now we are ready for production as all formalities and necessary regulatory approvals are in hand. We have proved 99.999% efficacy. We have developed a product that is a blend of Natural products and Modern Nanotechnology. This traditional knowledge is a solution to mitigate and address the spread of COVID-19 and also other virus variants. We have many proprietary combinations in this CoviRaksha and will produce it as over the counter product. ”

The medicine comes as a roll-on bottle with 10ml as the quantity. The silver colloid based liquid that has can be used for both prophylaxis and treatment of Covid-19 and Black Fungus. According to the lab, the bottle can help protect from the virus for a minimum of 3 hours.

Management consultant Venu Sharma said, “We have already made arrangements for production and in need of an investment partner for scaling up. We want this product series to be reaching the globe ASAP. Covid will stay with us for more time with different forms and maybe in new virus variants.”

Developed by Nuthan Labs in collaboration with the Indian Institute of Science, Bengaluru, the product has received a nod from the Ayush Department of Karnataka, while it is still awaiting a nod from the central department.

Speaking about the costing of the product, Venu Sharma said, "for a small minimum quantity, the costing becomes high, with an 18% GST and distribution model in hand the MRP will be near Rs.300-350/- as of now. But by mass production and better cost of a fund - CoviRaksha will be 20 to 30% cheaper."

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal

www.freepressjournal.in